ADIPOR1 (Adiponectin Receptor 1) is a cell membrane protein that binds adiponectin, a hormone involved in regulating glucose metabolism, fatty acid oxidation, and insulin sensitivity. As a key component of metabolic signaling pathways, ADIPOR1 activates AMP-activated protein kinase (AMPK) and peroxisome proliferator-activated receptor alpha (PPARα), promoting energy homeostasis and anti-inflammatory responses. Dysregulation of ADIPOR1 expression or function has been linked to metabolic disorders, including obesity, type 2 diabetes, and cardiovascular diseases, making it a significant target for biomedical research.
ADIPOR1 antibodies are essential tools for studying the receptor's expression, localization, and molecular interactions. These antibodies are typically developed using immunogenic peptides derived from specific regions of the human ADIPOR1 protein (e.g., N-terminal or C-terminal domains) and validated for applications such as Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and flow cytometry. High-quality ADIPOR1 antibodies demonstrate specificity through knockout validation or siRNA-mediated silencing controls, ensuring reliable detection in tissues like skeletal muscle, liver, and adipose tissue where the receptor is abundantly expressed.
In research, ADIPOR1 antibodies help elucidate mechanisms underlying metabolic diseases and evaluate therapeutic interventions targeting adiponectin signaling. They also aid in exploring ADIPOR1's role in cancer progression, neurodegenerative disorders, and aging-related pathologies. Commercial antibodies often include recombinant proteins or epitope tags to enhance reproducibility, supporting both basic and translational studies aimed at understanding metabolic regulation and developing precision therapies.